Advances in Ophthalmic Optogenetics: Approaches and Applications
Open accessThe DOI matches its Crossref record; 96 of the 99 references it cites were found in a registry or an index.
Abstract
Recent advances in optogenetics hold promise for vision restoration in degenerative eye diseases. Optogenetics refers to techniques that use light to control the cellular activity of targeted cells. Although optogenetics is a relatively new technology, multiple therapeutic options are already being explored in pre-clinical and phase I/II clinical trials with the aim of developing novel, safe, and effective treatments for major blinding eye diseases, such as glaucoma and retinitis pigmentosa. Optogenetic approaches to visual restoration are primarily aimed at replacing lost or dysfunctional photoreceptors by inserting light-sensitive proteins into downstream retinal neurons that have no intrinsic light sensitivity. Such approaches are attractive because they are agnostic to the genetic causes of retinal degeneration, which raises hopes that all forms of retinal dystrophic and degenerative diseases could become treatable. Optogenetic strategies can also have a far-reaching impact on translational research by serving as important tools to study the pathogenesis of retinal degeneration and to identify clinically relevant therapeutic targets. For example, the CRY-CIBN optogenetic system has been recently applied to animal models of glaucoma, suggesting a potential role of OCRL in the regulation of intraocular pressure in trabecular meshwork. As optogenetic strategies are being intensely investigated, it appears crucial to consider the opportunities and challenges such therapies may offer. Here, we review the more recent promising optogenetic molecules, vectors, and applications of optogenetics for the treatment of retinal degeneration and glaucoma. We also summarize the preliminary results of ongoing clinical trials for visual restoration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, optogenetics still require optimization to allow for complex visual processing and to increase the sensitivity of the proteins that are currently used.10,15”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040
Tham, Y.-C., Li, X., Wong, T. Y., Quigley, H. A., Aung, T., & Cheng, C.-Y. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.013 · Cited by 7,159
(2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.03.057 · Cited by 4,396
Steinmetz, J. D., Bourne, R. R. A., Briant, P. S., Flaxman, S. R., Taylor, H. R. B., Jonas, J. B., Abdoli, A. A., Abrha, W. A., Abualhasan, A., Abu-Gharbieh, E. G., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30489-7 · Cited by 3,189
(2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00538-9 · Cited by 2,780
Neurodegenerative Disorders: Parkinson's Disease and Huntington's Disease
Hague, S., Klaffke, S., & Bandmann, O. (2006) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781860948961_0007 · Cited by 2,767
Gordon, M. O. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.6.714 · Cited by 2,626
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Independent optical excitation of distinct neural populations
Klapoetke, N. C., Murata, Y., Kim, S. S., Pulver, S. R., Birdsey-Benson, A., Cho, Y. K., Morimoto, T. K., Chuong, A. S., Carpenter, E. J., Tian, Z., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2836 · Cited by 2,344
Weinreb, R. N., & Khaw, P. T. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16257-0 · Cited by 2,222
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“Clinical trials for gene therapy to treat LCA have demonstrated the safety and efficacy of subretinal delivery of transgenes to the retina via an AAV2 vector [92,93].”
Background
Research works printed but not linked: 1
- Martel, 2021, Optogenetic GS030 Therapy in Subjects with Retinitis Pigmentosa: Safety and Tolerability Up to Two Years After Treatment Administration in the Phase 1/2a PIONEER Study, Investigative Ophthalmology & Visual Science, 62, 3236
Cited by
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Gene Therapy for Inherited Retinal Diseases: From Laboratory Bench to Patient Bedside and Beyond
Brar, A. S., Parameswarappa, D. C., Takkar, B., Narayanan, R., Jalali, S., Mandal, S., Fujinami, K., & Padhy, S. K. (2023) · Ophthalmology and Therapy · doi:10.1007/s40123-023-00862-2 · Cited by 48
Camouflage Nanoparticles Enable in Situ Bioluminescence-Driven Optogenetic Therapy of Retinoblastoma
Ding, J., Lu, J., Zhang, Q., Xu, Y., Song, B., Wu, Y., Shi, H., Chu, B., Wang, H., & He, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c00470 · Cited by 30
AAV genome modification for efficient AAV production
Asaad, W., Volos, P., Maksimov, D. O., Khavina, E. M., Deviatkin, A. A., Mityaeva, O. N., & Volchkov, P. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15071 · Cited by 33
Current approaches to vision restoration using optogenetic therapy
Parnami, K., & Bhattacharyya, A. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1236826 · Cited by 28
Metadata
- Authors
- Prosseda, P. P., Tran, M., Kowal, T., Wang, B., & Sun, Y.
- Affiliations
- Stanford Medicine (US)
- University of Nevada, Reno (US)
- Corresponding author
- Sun, Yang
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2022-02-08
- Volume
- 12
- Issue
- 2
- Pages
- 269
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC8961521
- OpenAlex
- W4211263455
- Cited by
- 41
- References
- 99
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 7 · 2023: 12 · 2022: 4
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (NIH) / National Eye Institute (NEI) (K08-EY022058; R01-EY025295; F32-EY032775-01; T32-EY027816)
- U.S. Department of Veterans Affairs (CX001298)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Photoreceptor and optogenetics research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- optogenetics, vision restoration, retinal degeneration, glaucoma, retinitis pigmentosa, photoreceptor replacement, light-sensitive proteins, OCRL, intraocular pressure, trabecular meshwork, retinal dystrophy, gene therapy vectors, clinical trials
- MeSH terms
- Animals, Retina, Retinal Degeneration, Retinitis Pigmentosa, Vision, Ocular, Optogenetics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in Ophthalmic Optogenetics: Approaches and Applications. https://app.cochat.ai/papers/10.3390/biom12020269
- The paper
- Prosseda, P. P., Tran, M., Kowal, T., Wang, B., & Sun, Y. (2022). Advances in Ophthalmic Optogenetics: Approaches and Applications. Biomolecules. https://doi.org/10.3390/biom12020269
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
